EBT Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EBT Medical is pioneering a novel approach to treating pelvic health disorders by targeting the saphenous nerve, a newly discovered pathway for neuromodulation. Its lead program, NiNA, is a non-invasive neurostimulator and digital ecosystem for overactive bladder (OAB), designed to be an early-line therapy that avoids the side effects of drugs and the invasiveness of existing procedures. The company is venture-backed by firms like SV Health Investors and Genesys Capital and is led by a team with deep experience in medical devices and neuromodulation. EBT aims to disrupt the large but underserved OAB market by shifting neuromodulation from a last-resort treatment to a primary therapeutic option.

UrologyPelvic Health

Technology Platform

Non-invasive neuromodulation platform targeting the saphenous nerve to treat pelvic health disorders. Combines a wearable neurostimulator with a digital disease-management ecosystem for at-home use.

Opportunities

The overactive bladder market is vast, with 91% of patients untreated, representing a multi-billion dollar opportunity for a safe, effective, non-invasive therapy.

Success with NiNA would validate the saphenous nerve platform, enabling expansion into other large pelvic health indications like chronic pelvic pain and fecal incontinence.

Risk Factors

Key risks include the clinical and regulatory uncertainty of a novel therapeutic approach, the challenge of achieving physician adoption and payer reimbursement in a competitive market, and the execution risks inherent in a capital-intensive, early-stage medical device company.

Competitive Landscape

EBT competes in the OAB space against pharmaceutical therapies (anticholinergics, beta-3 agonists) and invasive/deviced therapies like PTNS, sacral neuromodulation (Medtronic, Axonics), and botox injections. NiNA's primary differentiation is its non-invasive, at-home, drug-free profile, aiming to be an early-line alternative to drugs.

More companies in United States →